Mark another tally for Pfizer and Merck KGaA’s Bavencio in the “loss” column.
It may be early days for Alnylam’s pioneering RNAi therapy Onpattro, but at least so far, sales look “disappointing,” according to one analyst.
The time is now for OTC drugmakers to examine and optimize marketing strategies on Amazon, an ad management company says.
Too-snug jeans in the back of the closet? Allergan’s newest spokescelebrity can relate, and she's talking about her CoolSculpting story.
Hutchison China MediTech’s Elunate, which was the first China-made drug to win a major oncology approval, has flopped in a key lung cancer trial.
AstraZeneca spent the last 16 months trying to keep investors’ hopes alive that its Mystic trial could succeed after an initial flop. But it didn’t.
AbbVie’s Orilissa snagged its first FDA approval over the summer, and now it’s looking to make it two.
New phase 3b data showed that, with just eight weeks of treatment, Mavyret could cure HCV patients with compensated cirrhosis.
Who wants drug prices in ads? Older people, that’s who.
Merck’s Keytruda is looking to beat its immuno-oncology rivals into yet another market, and it just posted the data that could get the job done.
